Hemostemix Inc.
Symbol:
TSXV: HEM
OTCQB: HMTXF
Market Cap:
Private
Sector:
Biotechnology
Summary:
- Groundbreaking stem cell therapy technology built upon 10 years of clinical research
- Stem cells derived from the host are then further concentrated into Hemostemix patented product ACP-01 which has a multitude of applications
- The application of this treatment can be as drastic as rejuvenating limbs from gangrene (CLI) and can heal degenerative heart diseases
- Quick treatment period, within 7 days of blood extraction the respective individual will be treated with Hemostemixs proprietary ACP-01 technology with tangible results coming promptly after
- ACP-01, which is in Phase 2 clinical trials, has demonstrated high efficacy and has received recognition from the Chief of Cardiology at McGill University’s health center.
- With an open Non-Brokered Private Placement Hemostemix looks to raise up to 10 million units at a price of $0.12. Additionally there will be one half of one common share purchase warrant priced at $0.25 with a hold period of 24 months